SCHEMBL4106705

SCHEMBL4106705

Cc1ccc(C)c(-c2nc(N)nc3ccc(Cl)nc23)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.44
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
RECQL P46063 1/20 0.43
ADORA2A P29274 3/20 0.39
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
CASP3 P42574 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
NCK1 P16333 1/20 0.37
BACE1 P56817 1/20 0.37
DHFR P00374 6/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107761 0.89 HSP90AB1 (0.44) HSP90AB1MAPTKDM4EALDH1A1GAA
SCHEMBL4102481 0.86 HSP90AB1 (0.40) HSP90AB1MAPTADORA2ADHFR
SCHEMBL4106568 0.83 ADORA2A (0.57) HSP90AB1MAPTALDH1A1HPGDHSD17B10
SCHEMBL4774971 0.82 MAPT (0.38) HSP90AB1MAPTKDM4EADORA2ADHFR
SCHEMBL4112502 0.80 HSP90AB1 (0.43) HSP90AB1MAPTADORA2ANCK1BACE1
SCHEMBL4102985 0.80 HSP90AB1 (0.58) HSP90AB1MAPTKDM4EALDH1A1ADORA2A
SCHEMBL4108093 0.79 HSP90AB1 (0.45) HSP90AB1MAPTALDH1A1HPGDADORA2A
SCHEMBL4103265 0.78 HSP90AB1 (0.47) HSP90AB1ADORA2ARAB9ANCK1BACE1
SCHEMBL4107356 0.78 RAB9A (0.49) HSP90AB1MAPTKDM4EALDH1A1ADORA2A
SCHEMBL4097023 0.78 ADORA2A (0.44) HSP90AB1MAPTADORA2ARAB9ABACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 US claimed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8338435-B2 Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 US disclosed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS PNPO, PNP, DPYD HSP90AB1 4606/4885MAPT 1752/4885KDM4E 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.